Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations

GDNF and the RET Receptor in Cancer: New Insights and Therapeutic Potential

(2019) Lois M. Mulligan   Frontiers in Physiology

Genotype and phenotype landscape of MEN2 in 554 medullary thyroid cancer patients: the BrasMEN study

(2019) Rui M B Maciel et al.   Endocrine Connections

Multiple endocrine neoplasia 2 in Cyprus: evidence for a founder effect

(2018) P. Fanis et al.   JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION

A synonymous RET substitution enhances the oncogenic effect of an in-cis missense mutation by increasing constitutive splicing efficiency

(2018) Valeria Pecce et al.   PLoS Genetics

Advances in the management of MEN2: from improved surgical and medical treatment to novel kinase inhibitors

(2017) Samuel A Wells   ENDOCRINE-RELATED CANCER

New insights in the molecular signature of advanced medullary thyroid cancer: evidence of a bad outcome of cases with doubleRETmutations

(2016) Cristina Romei et al.   JOURNAL OF MEDICAL GENETICS

A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma

(2016) Cristina Romei et al.   Nature Reviews Endocrinology

RETY791F Variant Does Not Increase the Risk for Medullary Thyroid Carcinoma

(2015) Rodrigo A. Toledo et al.   THYROID

Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma

(2015) Samuel A. Wells et al.   THYROID

Surgical Curability of Medullary Thyroid Cancer in Multiple Endocrine Neoplasia 2B

(2013) Michael Brauckhoff et al.   ANNALS OF SURGERY

High prevalence of exon 8 G533C mutation in apparently sporadic medullary thyroid carcinoma in Greece

(2012) H. L. Sarika et al.   CLINICAL ENDOCRINOLOGY

Genotype-phenotype correlation in multiple endocrine neoplasia type 2

(2012) F Raue et al.   Clinics

Low Prevalence of the Somatic M918T RET Mutation in Micro-Medullary Thyroid Cancer

(2012) Cristina Romei et al.   THYROID

Genetic and Clinical Features of Multiple Endocrine Neoplasia Types 1 and 2

(2012) C. Romei et al.   Journal of Oncology

In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer

(2011) B Cosci et al.   ENDOCRINE-RELATED CANCER

The Timing of Total Thyroidectomy inRETGene Mutation Carriers Could Be Personalized and Safely Planned on the Basis of Serum Calcitonin: 18 Years Experience at One Single Center

(2011) Rossella Elisei et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Predicting Phenotypic Severity of Uncertain Gene Variants in the RET Proto-Oncogene

(2011) David K. Crockett et al.   PLoS One

Multiple endocrine neoplasia type 2

(2010) Nelson Wohllk et al.   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM

RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC)

(2010) C. Romei et al.   CLINICAL ENDOCRINOLOGY

Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes

(2010) Cristina Romei et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Multiple endocrine neoplasia type 2RETprotooncogene database: Repository of MEN2-associatedRETsequence variation and reference for genotype/phenotype correlations

(2009) Rebecca L. Margraf et al.   HUMAN MUTATION

Familial prevalence and age of RET germline mutations: implications for screening

(2008) Andreas Machens et al.   CLINICAL ENDOCRINOLOGY